Gene therapy fault puts medtech under spotlight:
This article was originally published in Clinica
Italy, France, Germany and the US have temporarily halted gene therapy trials, after a French patient being treated for x-linked severe combined immunodeficiency (X-SCID) developed leukaemia. The UK, however, has stopped short of halting such research, in the belief that the benefits far outweigh the risks. In early 2000, the US FDA halted an angiogenesis trial using vascular endothelial growth-factor 2 (VEGF-2), after Vascular Genetics delayed reporting the death of two patients (see Clinica No 899, p 22). The scientific community, however, gave unqualified support for the safety and potential efficacy of gene therapy (see Clinica No 900, p 15). Worldwide there are 636 completed, ongoing or pending gene therapy trials, used to treat a range of conditions, from advanced breast cancer to coronary heart disease.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.